Rockwell Medical (NASDAQ: RMTI) announced its fourth-quarter financial results, with revenues falling short of expectations and declining compared to a year earlier. The company’s earnings per share met analyst estimates but decreased from the previous year.
The company reported adjusted earnings per share of $0.02 for the fourth quarter, aligning with analyst estimates. This figure reflects a decrease from the $0.04 per share recorded a year ago.
Revenues for the fourth quarter amounted to $18.35 million, missing consensus estimates by $0.23 million and decreasing from $24.66 million a year earlier.
Gross margin for the fourth quarter was 21 percent, marking an improvement from 15 percent in the same period last year. Adjusted EBITDA for the fourth quarter was $1.0 million, compared to $1.3 million in the same period last year.
The company provided a fiscal year 2026 revenue outlook ranging from $65.00 million to $70.00 million, which is below the analyst expectations of $75.15 million.
Mark Strobeck, Ph.D., President and CEO of Rockwell Medical, stated, “We made significant changes internally to further align our infrastructure with demand. As a result, our gross margin for the full-year 2025 was in line with gross margin for 2024, and we delivered one of the highest quarterly gross margins in the Company’s history in the fourth quarter 2025.”
 reported Q4 adjusted EPS of $0.02, meeting analyst estimates but down from $0.04 a year ago. Revenue was $18.35 million, missing estimates by $0.23 million and down from $24.66 million last year.){kind=link}